# Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

> **NCT00454337** · PHASE3 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 170 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** FTC/TDF + EFV or LPV/R +T20
- **DRUG:** FTC/TDF + EFV or LPV/R

## Key facts

- **NCT ID:** NCT00454337
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454337, "Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00454337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*